Violeta Serra
Has grant
Group Leader
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
PARPiPRED, a diagnostic test that facilitates personalised medicine for cancer treatment
Open Date: 2020-05-01
Close Date: 2021-04-01
Grant: Close
RAD51predict: Patient stratification based on DNA repair functionality for cancer precision medicine
Open Date: 2020-01-01
Close Date: 2022-01-01
Grant: Close
Liquid biopsies for the identification of mechanisms of resistance to PARP inhibitors in BRCA1/2-associated cancers
Open Date: 2020-01-01
Close Date: 2022-01-01
Grant: Close
Development of a liquid biopsy test to assess the homologous recombination function status in BRCA1/2 mutation carriers with breast cancer to inform therapy selection
Open Date: 2019-01-01
Close Date: 2021-01-01
Grant: Close
Modulation of androgen receptor signalling as a therapeutic strategy for oestrogen receptor-positive metastatic breast cancer
Open Date: 2019-01-01
Close Date: 2021-01-01
Articles (31)
Year:
2026
Evaluation of RAD51 scores in CCA_PDXs and CCA patients. (A) RAD51 scores of CCA_PDXs and their matched originating biopsy samples. (B) RAD51 scores evaluated in PDX85 (IDH1mut) treated as for Figure 4C.
Year:
2025
Growth of cells derived from CCA_PDXs in the 3D ex vivo culture system. (A) Representative bright-field images of cells derived from indicated CCA_PDXs and cultured ex vivo. Images are from days 0, 3, 7, and 10. Scale bar, 1 mm.
Year:
2025
Histopathologic characterization of CCA_PDXs. (A) Histologic and immunohistochemical images of CCA_PDXs. H&E staining, and immunohistochemical staining of KRT19 (CCA marker) and HepPar1 (HCC marker) were shown. CCA_PDX samples were collected at passage 1 (PDX41, PDX96, PDX118, PDX123, PDX132, and PDX133) or passage 2 (PDX58, PDX62, PDX67, PDX68.2, PDX75, PDX75.2, PDX78, PDX84, PDX85, PDX104, PDX119, and PDX120). Scale bar, 250 µm.
Year:
2025
Absence of PARP inhibitor efficacy in IDH1mut, ARID1Amut, or BAP1mut CCA_PDXs. (A) Dose-response curves of niraparib for a panel of tumoroids derived from CCA_PDXs. Cell viability was determined using Cell Titer-Glo assay 7 days after the treatment initiation. Data are mean ± s.d. from independent biological replicates. PDX41, n=3; PDX78, n=3; PDX85, n=6; PDX75, n=2; PDX75.2, n=2; PDX118, n=3; PDX133, n=3. (B) Half-maximal inhibitory concentration (IC50) of niraparib in tumoroids derived from CCA_PDXs. (C) Representative images of immunohistochemical staining for a cell proliferation marker (Ki67) and apoptosis marker cleaved caspase 3 in PDX85 cells treated as for Fig 4C. (D) Representative images of immunohistochemical staining for cell proliferation marker (Ki67) and apoptosis marker cleaved caspase 3 in PDX78 treated as for Fig 4D. Scale bar, 250 µm.
Year:
2025
Genomic rearrangements resulting in FGFR2 fusions. (A) Genomic rearrangements resulting in FGFR2 fusion identified in CCA_PDX and the corresponding biopsy samples. Fusion partner genes, their accession number, breakpoints, and predicted chimeric protein products are indicated.
Year:
2025
Homologous recombination deficiency (HRD) contributes to genomic instability and leads to sensitivity to PARP inhibitors (PARPi). HRD also activates the cyclic GMP–AMP synthase (cGAS)–stimulator of interferon genes (STING)–interferon pathway, highlighting the need to understand the impact of cGAS–STING–IFN signaling on PARPi efficacy. In this study, we analyzed a cohort of 35 breast cancer patient-derived xenografts and mouse-derived allografts. PARPi sensitivity correlated with HRD, increased genomic instability, and activation of the cGAS–STING–IFN signaling pathway. Single-cell analyses showed that IFN signaling and IFN-based immune interactions were suppressed in preclinical models with acquired resistance to PARPi, lacking concomitant clonal expansion of functional CD8 + T cells. However, the combination of a PARPi and a novel STING agonist (STINGa) increased immune infiltration and resulted in superior antitumor activity in these tumors. Notably, the efficacy of PARPi monotherapy and the combination treatment with a STINGa was dependent on natural killer (NK) cells. In agreement, patients with breast cancer with BRCA1/BRCA2 mutations and good responses to PARPi showed higher abundancy of CD56 + NK cells in the tumor microenvironment and treatment-engaged CD56 bright NK cells in the peripheral immune compartment, compared with those with poor responses. Therefore, these findings propose the combination of PARPis and a STINGa as a potential novel strategy to enhance the therapeutic response in patients with acquired PARPi resistance and highlight a pivotal role of NK cells in the PARPi antitumor activity. Significance: PARP inhibitor sensitivity is associated with cGAS–STING–IFN signaling, which can be harnessed by combining PARP inhibitors with STING agonists to overcome acquired resistance and requires NK cells to mediate antitumor immunity. See related commentary by Gohari et al., p. 1747
Year:
2025
Purpose: The randomized GeparOLA trial reported comparable pathologic complete response (pCR) rates with neoadjuvant treatment containing olaparib versus carboplatin. In this study, we evaluate the association between functional homologous recombination deficiency (HRD) by RAD51 foci and pCR and the potential of improving patient selection by combining RAD51 and stromal tumor-infiltrating lymphocytes. Patients and Methods: This is a post hoc blinded biomarker analysis from the randomized GeparOLA trial. Patients with early-stage HER2-negative breast cancer and HRD assessed by Myriad MyChoice or BRCA1/BRCA2 mutations were randomized 1:1 to receive (i) paclitaxel plus olaparib or (ii) paclitaxel plus carboplatin, both followed by epirubicin/cyclophosphamide. Functional HRD was predefined as a RAD51 score ≤10% (RAD51-low). Results: Overall, 90 of 97 (92.8%) samples were evaluable for RAD51 testing, and 72 of 90 (80.0%) were RAD51-low. The pCR rate in patients with RAD51-low tumors was 66.7% (48/72), whereas it decreased to 22.2% (4/18) in those with RAD51-high. In the multivariable model including clinicopathologic factors and treatment, the RAD51 score remained significantly associated with pCR (OR = 12.03; 95% confidence interval, 2.60–55.73; P = 0.002). Patients with RAD51-low and high stromal tumor-infiltrating lymphocytes in their tumors achieved a pCR rate of 75.0% (27/36). Similar results were observed for olaparib or carboplatin. In the exploratory disease-free survival analysis, no differences were observed between RAD51 groups (high vs. low: HR = 0.85; 95% confidence interval, 0.25–2.97). Conclusions: In a preselected population with HRD, according to a genetic test, RAD51 testing identifies patients with different pCR rates under PARP inhibitor-based or platinum-based therapies. Future biomarker-driven studies should consider this information to refine stratification factors and to improve patient selection.
Year:
2025
Purpose: To determine the ability of RAD51 foci to predict platinum chemotherapy response in high-grade serous ovarian cancer (HGSOC) patient-derived samples. Experimental Design: RAD51 and γH2AX nuclear foci were evaluated by immunofluorescence in HGSOC patient-derived cell lines ( n = 5), organoids ( n = 11), and formalin-fixed, paraffin-embedded tumor samples (discovery n = 31, validation n = 148). Samples were defined as RAD51-High if >10% of geminin-positive cells had ≥5 RAD51 foci. Associations between RAD51 scores, platinum chemotherapy response, and survival were evaluated. Results: RAD51 scores correlated with in vitro response to platinum chemotherapy in established and primary ovarian cancer cell lines (Pearson r = 0.96, P = 0.01). Organoids from platinum-nonresponsive tumors had significantly higher RAD51 scores than those from platinum-responsive tumors ( P P P = 0.05). The RAD51 score was predictive of chemotherapy response score [AUC, 0.90; 95% confidence interval (CI), 0.78–1.0; P P P P = 0.003) than RAD51-High status. Conclusions: RAD51 foci are a robust marker of platinum chemotherapy response and survival in ovarian cancer. The utility of RAD51 foci as a predictive biomarker for HGSOC should be tested in clinical trials.
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (47)
Carsten Denkert
Philipps-Universität Marburg
SONIA PERNAS SIMON
Associate Professor
University of Barcelona
Mary M. Mullen
Washington University
Aleix Prat
Director Clínic Barcelona Comprehensive Cancer Centre (4C)
Hospital Clínic de Barcelona
Mark A. Dickson
-
Anthony Turpin
Centre Hospitalier Régional Universitaire de Lille
Samuel Singer
Vincent Astor Chair of Clinical Research
Memorial Sloan Kettering Cancer Center
Heura Domènech Garcia
Vall d'Hebron Institute of Oncology
Dineo Khabele
Professor and Chair
Washington University in St. Louis
Raghu Kataru
Senior Research Scientist
Memorial Sloan Kettering Cancer Center
Nguan Soon Tan
Professor
Nanyang Technological University (NTU)
Jelle Wesseling
Professor of Breast Pathology
Leiden University Medical Center
Rodrigo Gularte Mérida
Senior Research Scientist
Memorial Sloan Kettering Cancer Center
Joaquin Arribas
Research Director
Hospital del Mar
Ana Vivancos
Principal Investigator
Vall d'Hebron Institute of Oncology
Joan Seoane
Hospital Universitari Vall d'Hebron
ENRIQUE JAVIER ARENAS LAHUERTA
Institute for Research in Biomedicine
Elisabetta Marangoni
Institut Curie
Judith Balmaña
Head
Hospital Universitari Vall d'Hebron
Andrea Hagemann
Professor
Washington University School of Medicine
Winona Oliveros
KTH Royal Institute of Technology
Cindy Neuzillet
PU PH
Université de Versailles Saint-Quentin-en-Yvelines
Josep Tabernero
Associate Professor Faculty of Medicine
Universitat de Vic - Universitat Central de Catalunya
Mathew A. Powell
Professor
Washington University in St. Louis
Tanja Fehm
Professor
University Hospital Düsseldorf
Lulu Sun
Washington University
Lara Nonell
Head of bioinformatics unit
Vall d'Hebron Institute of Oncology
Nima Mosammaparast
Washington University in St. Louis
Marta Mele
Group leader
Barcelona Supercomputing Center
Oscar Pozo
Miguel Servet II
Institut Hospital del Mar d'Investigacions Mèdiques
Thomas Karn
Goethe University Frankfurt
Peter Fasching
-
Shariska Harrington
Assistant Professor
Mayo Clinic
Catrin Lutz
The Netherlands Cancer Institute
Guillermo Villacampa Javierre
Biostatistician
Vall d´Hebron Institute of Oncology
Teresa Macarulla
Head of Gastrointestinal and Endocrine Tumor Unit
Hospital Clínic de Barcelona
Paolo Nuciforo
Head
Vall d´Hebron Institut d´Oncologia
Martin Espinosa-Bravo
Head of Breast Surgical Unit
-
Ciara Kelly
-
Sandra Peiró
Head of the Chromatin Dynamics in Cancer Group
Vall d'Hebron Institute of Oncology
Marta Kovatcheva
Group Leader (Assistant Professor Equivalent)
IFOM – The AIRC Institute of Molecular Oncology
Andrew Koff
Sloan Kettering Institute
Anna Pascual Reguant
Team Lead
Centro Nacional de Análisis Genómico (CNAG)
Lindsay Kuroki
Assistant Professor
Washington University School of Medicine
MARIA TERESA MARTINEZ
-
Dimitris Polychronopoulos
Chief Data Officer and co-founder
CureCollect
TIAN TIAN
Vall d'Hebron Institute of Oncology
Make your next move.
Prepare your application
Review drafts before you send them.